Phase1/-2 study of pomalidomide in myelofibrosis

Ruben Mesa, Animesh D. Pardanani, Kebede Hussein, Wenting Wu, Susan Schwager, Mark R. Litzow, William J. Hogan, Ayalew Tefferi

Research output: Contribution to journalArticle

71 Citations (Scopus)

Abstract

We conducted a dose-escalation study to see if higher doses of Pomalidomide (previously shown to be safe and effective for myelofibrosis-associated anemia at 0.5 mg/day [with prednisone] or 2.0 mg/day) increased anemia responses. 3.0 mg/d given for 21 of 28 consecutive days was the maximum-tolerated dose (MTD), with myelosuppression being dose limiting. Nonresponders at the MTD had their dose decreased and the therapy interval increased to daily. Seven of 19 subjects had an anemia-response and two had a spleen response. Most responses occurred after dose-reduction to 0.5 mg/d, suggesting higher doses are associated with increasing myelosuppression without increasing (or possibly decreasing) efficacy.

Original languageEnglish (US)
Pages (from-to)129-130
Number of pages2
JournalAmerican Journal of Hematology
Volume85
Issue number2
DOIs
StatePublished - Feb 1 2010
Externally publishedYes

Fingerprint

Primary Myelofibrosis
Anemia
Maximum Tolerated Dose
Prednisone
Spleen
pomalidomide
Therapeutics

ASJC Scopus subject areas

  • Hematology

Cite this

Mesa, R., Pardanani, A. D., Hussein, K., Wu, W., Schwager, S., Litzow, M. R., ... Tefferi, A. (2010). Phase1/-2 study of pomalidomide in myelofibrosis. American Journal of Hematology, 85(2), 129-130. https://doi.org/10.1002/ajh.21598

Phase1/-2 study of pomalidomide in myelofibrosis. / Mesa, Ruben; Pardanani, Animesh D.; Hussein, Kebede; Wu, Wenting; Schwager, Susan; Litzow, Mark R.; Hogan, William J.; Tefferi, Ayalew.

In: American Journal of Hematology, Vol. 85, No. 2, 01.02.2010, p. 129-130.

Research output: Contribution to journalArticle

Mesa, R, Pardanani, AD, Hussein, K, Wu, W, Schwager, S, Litzow, MR, Hogan, WJ & Tefferi, A 2010, 'Phase1/-2 study of pomalidomide in myelofibrosis', American Journal of Hematology, vol. 85, no. 2, pp. 129-130. https://doi.org/10.1002/ajh.21598
Mesa R, Pardanani AD, Hussein K, Wu W, Schwager S, Litzow MR et al. Phase1/-2 study of pomalidomide in myelofibrosis. American Journal of Hematology. 2010 Feb 1;85(2):129-130. https://doi.org/10.1002/ajh.21598
Mesa, Ruben ; Pardanani, Animesh D. ; Hussein, Kebede ; Wu, Wenting ; Schwager, Susan ; Litzow, Mark R. ; Hogan, William J. ; Tefferi, Ayalew. / Phase1/-2 study of pomalidomide in myelofibrosis. In: American Journal of Hematology. 2010 ; Vol. 85, No. 2. pp. 129-130.
@article{c10e368b2ca447a685099f15fe78f94f,
title = "Phase1/-2 study of pomalidomide in myelofibrosis",
abstract = "We conducted a dose-escalation study to see if higher doses of Pomalidomide (previously shown to be safe and effective for myelofibrosis-associated anemia at 0.5 mg/day [with prednisone] or 2.0 mg/day) increased anemia responses. 3.0 mg/d given for 21 of 28 consecutive days was the maximum-tolerated dose (MTD), with myelosuppression being dose limiting. Nonresponders at the MTD had their dose decreased and the therapy interval increased to daily. Seven of 19 subjects had an anemia-response and two had a spleen response. Most responses occurred after dose-reduction to 0.5 mg/d, suggesting higher doses are associated with increasing myelosuppression without increasing (or possibly decreasing) efficacy.",
author = "Ruben Mesa and Pardanani, {Animesh D.} and Kebede Hussein and Wenting Wu and Susan Schwager and Litzow, {Mark R.} and Hogan, {William J.} and Ayalew Tefferi",
year = "2010",
month = "2",
day = "1",
doi = "10.1002/ajh.21598",
language = "English (US)",
volume = "85",
pages = "129--130",
journal = "American Journal of Hematology",
issn = "0361-8609",
publisher = "Wiley-Liss Inc.",
number = "2",

}

TY - JOUR

T1 - Phase1/-2 study of pomalidomide in myelofibrosis

AU - Mesa, Ruben

AU - Pardanani, Animesh D.

AU - Hussein, Kebede

AU - Wu, Wenting

AU - Schwager, Susan

AU - Litzow, Mark R.

AU - Hogan, William J.

AU - Tefferi, Ayalew

PY - 2010/2/1

Y1 - 2010/2/1

N2 - We conducted a dose-escalation study to see if higher doses of Pomalidomide (previously shown to be safe and effective for myelofibrosis-associated anemia at 0.5 mg/day [with prednisone] or 2.0 mg/day) increased anemia responses. 3.0 mg/d given for 21 of 28 consecutive days was the maximum-tolerated dose (MTD), with myelosuppression being dose limiting. Nonresponders at the MTD had their dose decreased and the therapy interval increased to daily. Seven of 19 subjects had an anemia-response and two had a spleen response. Most responses occurred after dose-reduction to 0.5 mg/d, suggesting higher doses are associated with increasing myelosuppression without increasing (or possibly decreasing) efficacy.

AB - We conducted a dose-escalation study to see if higher doses of Pomalidomide (previously shown to be safe and effective for myelofibrosis-associated anemia at 0.5 mg/day [with prednisone] or 2.0 mg/day) increased anemia responses. 3.0 mg/d given for 21 of 28 consecutive days was the maximum-tolerated dose (MTD), with myelosuppression being dose limiting. Nonresponders at the MTD had their dose decreased and the therapy interval increased to daily. Seven of 19 subjects had an anemia-response and two had a spleen response. Most responses occurred after dose-reduction to 0.5 mg/d, suggesting higher doses are associated with increasing myelosuppression without increasing (or possibly decreasing) efficacy.

UR - http://www.scopus.com/inward/record.url?scp=75449087842&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=75449087842&partnerID=8YFLogxK

U2 - 10.1002/ajh.21598

DO - 10.1002/ajh.21598

M3 - Article

C2 - 20052748

AN - SCOPUS:75449087842

VL - 85

SP - 129

EP - 130

JO - American Journal of Hematology

JF - American Journal of Hematology

SN - 0361-8609

IS - 2

ER -